Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

Recent & Breaking News (TSXV:BTI)

Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration

GlobeNewswire June 30, 2021

Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners

GlobeNewswire June 29, 2021

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

GlobeNewswire June 25, 2021

Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million

GlobeNewswire June 22, 2021

Bioasis Announces Publication Validating its xB³ (TM) Platform Technology for CNS Therapeutics

GlobeNewswire June 3, 2021

Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration

GlobeNewswire March 31, 2021

Bioasis Announces Publication of CNS Delivery of siRNA via xB³ (TM) Platform Technology

GlobeNewswire March 29, 2021

Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing

GlobeNewswire March 24, 2021

Bioasis Technologies Inc. Announces Warrant Extension and Repricing

GlobeNewswire March 22, 2021

Bioasis to Attend and Present at Upcoming Investor and Industry Conferences

GlobeNewswire March 8, 2021

Bioasis Announces Shares for Debt Transaction

GlobeNewswire February 10, 2021

Bioasis Announces $200,000 Non-Brokered Private Placement

GlobeNewswire January 29, 2021

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020

GlobeNewswire January 27, 2021

Bioasis Announces Stock Option Grant

GlobeNewswire January 22, 2021

Bioasis to Present at Upcoming Industry Conferences

GlobeNewswire January 4, 2021

Bioasis Announces Annual General Meeting Results

GlobeNewswire December 10, 2020

Bioasis Announces Annual General Meeting Details

GlobeNewswire November 10, 2020

Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group-Bioasis Strategic Alliance to XOMA Corporation

GlobeNewswire November 3, 2020

XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group-Bioasis Strategic Alliance

GlobeNewswire November 3, 2020

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020

GlobeNewswire October 29, 2020